GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

By Thomson Reuters Aug 12, 2022 | 3:24 AM

LONDON (Reuters) – Shares in GSK, Sanofi

The companies’ share prices had fallen sharply this week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug’s withdrawal from markets in 2019 and 2020. The first U.S. trial is expected to start this month.

(Reporting by Natalie Grover in London; Editing by David Goodman)